Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Capital Expenditures (2021 - 2025)

Rxo's Capital Expenditures history spans 5 years, with the latest figure at $16.0 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 33.33% year-over-year to $16.0 million; the TTM value through Dec 2025 reached $59.0 million, up 31.11%, while the annual FY2025 figure was $59.0 million, 31.11% up from the prior year.
  • Capital Expenditures reached $16.0 million in Q4 2025 per RXO's latest filing, up from $14.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $18.0 million in Q4 2022 to a low of $9.0 million in Q4 2021.
  • Average Capital Expenditures over 5 years is $13.8 million, with a median of $14.0 million recorded in 2025.
  • Peak YoY movement for Capital Expenditures: soared 100.0% in 2022, then plummeted 38.89% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $9.0 million in 2021, then skyrocketed by 100.0% to $18.0 million in 2022, then changed by 0.0% to $18.0 million in 2023, then tumbled by 33.33% to $12.0 million in 2024, then soared by 33.33% to $16.0 million in 2025.
  • Per Business Quant, the three most recent readings for RXO's Capital Expenditures are $16.0 million (Q4 2025), $14.0 million (Q3 2025), and $14.0 million (Q2 2025).